DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Benazepril plus hydrochlorothiazide (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Principal Investigator, Affiliation: Novartis Pharmaceuticals


This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.

Clinical Details

Official title: Efficacy and Safety of the Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Benazepril

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Change in diastolic blood pressure from baseline to week 8

Secondary outcome:

Change in systolic blood pressure from baseline to week 8

Proportion of patients with blood pressure less than 140/90 mmHg at week 8

Ambulant blood pressure monitoring profiles at baseline and week 8


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Male or female patients, age 18 or older

- Given informed consent

- Diagnosed as having mild to moderate essential hypertension

Exclusion Criteria:

- Severe hypertension

- Significant preexisting cardiovascular and cerebrovascular disease

- Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II

- Advanced renal impairment

Other protocol-defined inclusion/exclusion criteria may apply.

Locations and Contacts

Novartis, Beijing, China
Additional Information

Starting date: July 2006
Last updated: July 6, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017